Trial Profile
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Carvedilol (Primary)
- Indications Heart disorders
- Focus Registrational; Therapeutic Use
- 24 Jan 2023 This study protocol amended as Adverse events primary endpoints has been removed and study focus is shifted to Tu only.
- 13 May 2021 Planned End Date changed from 1 Feb 2023 to 1 Jan 2029.
- 13 May 2021 Planned primary completion date changed from 1 Feb 2023 to 1 Jan 2029.